Back to search
FDAFDA · Food and drugs·Recall number Z-2290-2020

therascreen EGFR RGQ PCR Kit (24), Reference Number REF 870121

Published June 17, 2020 · Recall initiated: April 8, 2020

Summary

FDA records medical device Class II recall Z-2290-2020, published June 17, 2020 and initiated April 8, 2020. Recalling firm: Qiagen Sciences LLC; Status: Terminated; Reported quantity: 530 kits within expiry; Lot: All lots. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

There is a risk for a false mutation positive result in rare cases resulting from a fluorescence artefact. In these rare cases, the controls pass correctly, while a fluorescence artefact in the mutation assay causes an incorrect valid mutation positive result.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Qiagen Sciences LLC
Distributor
US Nationwide.
Lot
All lots
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was therascreen EGFR RGQ PCR Kit (24), Reference Number REF 870121 recalled?

Yes. FDA published recall Z-2290-2020 on June 17, 2020. Reported hazard: There is a risk for a false mutation positive result in rare cases resulting from a fluorescence artefact. In these rare cases, the controls pass correctly, while a fluorescence artefact in the mutation assay causes an incorrect valid mutation positive result.

What should I do if I have this product?

Voluntary: Firm initiated · Letter